2014 Competition Prospecting Side effects 
Pharmaceutical Technology
NOVEMBER 30, 2022
In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021.
Pharmaceutical Technology
NOVEMBER 30, 2022
In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021.
Expert insights. Personalized for you.
105 
Let's personalize your content